Abstract:BACKGROUND:Oxaliplatin is one of the most commonly used chemotherapeutic agent for the treatment of various cancers, including gastric cancer. It has, however, a narrow therapeutic index due to its toxicity and the occurrence of drug resistance. Hence, it is of great significance to develop novel therapies to potentiate the anti-tumor effect and reduce the toxicity of oxaliplatin. In our previous study, we demonstrated that ethaselen (BBSKE), an inhibitor of thioredoxin reductase, effectively inhibited the growth of gastric cancer cells and promoted apoptosis in vitro. In the present study, we investigated whether BBSKE can potentiate the anti-tumor effect of oxaliplatin in gastric cancer in vivo and vitro.METHODS:Cellular apoptosis and ROS levels were analyzed by flow cytometry. Thioredoxin reductase 1 (TrxR1) activity in gastric cancer cells, organoid and tumor tissues was determined by using the endpoint insulin reduction assay. Western blot was used to analyze the expressions of the indicated proteins. Nude mice xenograft models were used to test the effects of BBSKE and oxaliplatin combinations on gastric cancer cell growth in vivo. In addition, we also used the combined treatment of BBSKE and oxaliplatin in three cases of gastric cancer Patient-Derived organoid (GC-PDO) to detect the anti-tumor effect.RESULTS:We found that BBSKE significantly enhanced oxaliplatin-induced growth inhibition in gastric cancer cells by inhibiting TrxR1 activity. Because of the inhibition of TrxR1 activity, BBSKE synergized with oxaliplatin to enhance the production of ROS and activate p38 and JNK signaling pathways which eventually induced apoptosis of gastric cancer cells. In vivo, we also found that BBSKE synergized with oxaliplatin to suppress the gastric cancer tumor growth in xenograft nude mice model, accompanied by the reduced TrxR1 activity. Remarkably, we found that BBSKE attenuated body weight loss evoked by oxaliplatin treatment. We also used three cases of GC-PDO and found that the combined treatment of BBSKE and oxaliplatin dramatically inhibited the growth and viability of GC-PDO with increased ROS level, decreased TrxR1 activity and enhanced apoptosis.CONCLUSIONS:This study elucidates the underlying mechanisms of synergistic effect of BBSKE and oxaliplatin, and suggests that the combined treatment has potential value in gastric cancer therapy.

Cetuximab Enhances the Effect of Oxaliplatin on Hypoxic Gastric Cancer Cell Lines.

The effects of cetuximab in combination with docetaxel for the acquired resistance to EGFR-TKI in non-small cell lung cancer cells

Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan

Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells During Treatment of Colorectal Cancer

Cetuximab Enhanced the Efficacy of Chemotherapeutic Agent in ABCB1/P-glycoprotein-overexpressing Cancer Cells.

Cetuximab enhances the efficiency of irinotecan through simultaneously inhibiting the MAPK signaling and ABCG2 in colorectal cancer cells

Cetuximab-induced insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells

Data from Cetuximab Reverses the Warburg Effect by Inhibiting HIF-1–Regulated LDH-A

Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

The Overexpression of ERCC-1 is Involved in the Resistance of Lung Cancer Cells to Cetuximab Combined with DDP.

Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer

Hypoxia-Inducible Factor-1 Alpha Contributes to Hypoxia-Induced Chemoresistance in Gastric Cancer

EGFR Gene Status Predicts Response and Survival Benefit in a Preclinical Gastric Cancer Trial Treating Patient-Derived Xenografts with Cetuximab

Combination of Cetuximab with Met Inhibitor in Control of Cetuximab-Resistant Oral Squamous Cell Carcinoma

Cetuximab Combined with FOLFOX4 As the First-Line Treatment for Advanced Gastric Cancer: Report of 25 Cases from a Single Institution

[Cetuximab in Combination with Chemotherapy for Patients with Gastrointestinal Cancer].

Up‐regulation of Survivin by AKT and Hypoxia‐inducible Factor 1α Contributes to Cisplatin Resistance in Gastric Cancer

Cetuximab enhances oridonin-induced apoptosis through mitochondrial pathway and endoplasmic reticulum stress in laryngeal squamous cell carcinoma cells

Ethaselen Synergizes with Oxaliplatin in Tumor Growth Inhibition by Inducing ROS Production and Inhibiting TrxR1 Activity in Gastric Cancer

GLUD1 Promotes Cetuximab Resistance in Metastasis Colorectal Cancer